{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:38:48Z","timestamp":1781275128903,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12185-025-04087-w","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T03:10:24Z","timestamp":1761275424000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone"],"prefix":"10.1007","volume":"123","author":[{"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"22","key":"4087_CR1","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood.V114.22.3866.3866","volume":"114","author":"M Teresa Petrucci","year":"2009","unstructured":"Teresa Petrucci M, Blau IW, Corradini P, Dimopoulos MA, Drach J, Giraldo P, et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study. Blood. 2009;114(22):3866. https:\/\/doi.org\/10.1182\/blood.V114.22.3866.3866.","journal-title":"Blood"},{"issue":"1","key":"4087_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44313-025-00055-9","volume":"60","author":"SH Jung","year":"2025","unstructured":"Jung SH, Koh Y, Kim MK, Kim JS, Moon JH, Min CK, et al. Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions. Blood Res. 2025;60(1):9. https:\/\/doi.org\/10.1007\/s44313-025-00055-9.","journal-title":"Blood Res"},{"issue":"12","key":"4087_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4087_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1411321.","journal-title":"N Engl J Med"},{"issue":"11","key":"4087_CR5","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.3324\/haematol.2024.285534","volume":"109","author":"JH Lee","year":"2024","unstructured":"Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, et al. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study. Haematologica. 2024;109(11):3681\u201392. https:\/\/doi.org\/10.3324\/haematol.2024.285534.","journal-title":"Haematologica"},{"key":"4087_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115157","volume":"215","author":"K Yong","year":"2025","unstructured":"Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, et al. Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1\u20133 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials. Eur J Cancer. 2025;215:115157. https:\/\/doi.org\/10.1016\/j.ejca.2024.115157.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4087_CR7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087. https:\/\/doi.org\/10.1186\/s12885-020-07503-y.","journal-title":"BMC Cancer"},{"issue":"11","key":"4087_CR8","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/leu.2010.190","volume":"24","author":"MQ Lacy","year":"2010","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934\u20139. https:\/\/doi.org\/10.1038\/leu.2010.190.","journal-title":"Leukemia"},{"issue":"20","key":"4087_CR9","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284\u201390. https:\/\/doi.org\/10.1182\/blood-2015-05-643320.","journal-title":"Blood"},{"issue":"8","key":"4087_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","volume":"32","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study. Leukemia. 2018;32(8):1803\u20137. https:\/\/doi.org\/10.1038\/s41375-018-0024-1.","journal-title":"Leukemia"},{"issue":"19","key":"4087_CR11","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1182\/bloodadvances.2022008866","volume":"7","author":"BA Derman","year":"2023","unstructured":"Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, et al. Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023;7(19):5703\u201312. https:\/\/doi.org\/10.1182\/bloodadvances.2022008866.","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"4087_CR12","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1182\/blood-2019-124376","volume":"134","author":"TJ Peterson","year":"2019","unstructured":"Peterson TJ, Korde N, Hassoun H, Mailankody S, Lesokhin AM, Hultcrantz M, et al. An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma. Blood. 2019;134(Supplement_1):5554. https:\/\/doi.org\/10.1182\/blood-2019-124376.","journal-title":"Blood"},{"issue":"8","key":"4087_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4087_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497\u2013503. https:\/\/doi.org\/10.1182\/blood-2016-02-700872.","journal-title":"Blood"},{"issue":"1","key":"4087_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38(1):143\u201351.","journal-title":"Biometrics"},{"issue":"2","key":"4087_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100\u201313. https:\/\/doi.org\/10.1038\/nrclinonc.2016.122.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3\u20134","key":"4087_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000322866","volume":"79","author":"I Hrusovsky","year":"2010","unstructured":"Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 2010;79(3\u20134):247\u201354. https:\/\/doi.org\/10.1159\/000322866.","journal-title":"Oncology"},{"key":"4087_CR18","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2012.13562","volume":"142","author":"C Taverna","year":"2012","unstructured":"Taverna C, Voegeli J, Trojan A, Olie RA, von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma\u2013a multicentre retrospective survey in Switzerland. Swiss Med Wkly. 2012;142:w13562. https:\/\/doi.org\/10.4414\/smw.2012.13562.","journal-title":"Swiss Med Wkly"},{"issue":"6","key":"4087_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394. https:\/\/doi.org\/10.1016\/s1470-2045(19)30152-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4087_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801\u201312. https:\/\/doi.org\/10.1016\/s1470-2045(21)00128-5.","journal-title":"Lancet Oncol"},{"issue":"19","key":"4087_CR21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1182\/bloodadvances.2024012640","volume":"8","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, et al. Real-world treatment patterns and outcomes in relapsed\/refractory multiple myeloma (1\u20133 prior lines): flatiron database. Blood Adv. 2024;8(19):5062\u201371. https:\/\/doi.org\/10.1182\/bloodadvances.2024012640.","journal-title":"Blood Adv"},{"issue":"8","key":"4087_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00277-021-04407-0","volume":"100","author":"JH Lee","year":"2021","unstructured":"Lee JH, Park Y, Kang KW, Lee JJ, Lee HS, Eom HS, et al. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol. 2021;100(8):2051\u20139. https:\/\/doi.org\/10.1007\/s00277-021-04407-0.","journal-title":"Ann Hematol"},{"issue":"2","key":"4087_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.56142\/jperm.22.0014","volume":"14","author":"M Ko","year":"2022","unstructured":"Ko M, Choi J, Kim S, Kim SH, Cho EJ, Cho YS, et al. Real-world data-based adverse drug reactions analysis of pomalidomide in patients with relapsed or refractory multiple myeloma. J Pharmacoepidemiol Risk Manag. 2022;14(2):149\u201357. https:\/\/doi.org\/10.56142\/jperm.22.0014.","journal-title":"J Pharmacoepidemiol Risk Manag"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04087-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:50:41Z","timestamp":1771339841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04087-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4087"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04087-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and the Declaration of Helsinki or comparable ethical standards. This study was approved by the institutional review boards of the respective institutions. (Approval numbers: SMC\u00a02021-03-147, GBIRB2021-485, KC21MIDS0854, NCC2022-0203, and DAUHIRB-21-192).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}